Loading…
← CockpitCompetitor Analysis › 6576.TWO Foresee Pharmaceuticals Co., Ltd.Open in the cockpit ↗

Foresee Pharmaceuticals Co., Ltd.6576.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum neutral 53
Mkt cap
$322M
US dollars, full cap
$/day
$186,425
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-56.8 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
114 days
12 Mar 2027
Close · TWDNT$69.90
1D-1.0%
1W-4.2%
1M-9.9%
3M-12.3%
6M-11.5%
YTD-13.3%
1Y-10.4%
ATR %3.1%
52w lowhigh25.4% off high

What Foresee Pharmaceuticals does

No business profile yet.

Foresee Pharmaceuticals at a glance

Size Foresee Pharmaceuticals (6576.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $322M, the 614th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$69.90 on 18 Nov 2026.

Performance Over six months the shares fell 11.5%, against -22.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 6.4% over the last twelve months (peer median +2.5%); the operating margin is -104.5% (peer median 3.7%).

Valuation It trades at 21.4× enterprise value to sales against a peer median of 3.3× (2nd most expensive of 19).

Capital Return on invested capital runs 56.8 points below its cost of capital (5.0% WACC).

Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 20266576.TWO 85Peer median 77
Six months, rebased to 100: Foresee Pharmaceuticals against the median of its 20 peers (local-currency closes).

Foresee Pharmaceuticals financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$471MNT$431MNT$419MNT$195MNT$302M
Revenue growth—+3%+115%-35%—
Gross profitNT$317MNT$236MNT$169MNT$50.1MNT$235M
EBITDA-NT$436M-NT$794M-NT$999M-NT$934M-NT$418M
Net incomeNT$22.5M-NT$883M-NT$1.08B-NT$1.04B-NT$473M
Free cash flow-NT$593M-NT$845M-NT$1.32B-NT$934M-NT$589M
Capital expenditureNT$54.7MNT$15.5MNT$156MNT$46.3MNT$58.1M
Total debtNT$398MNT$232MNT$260MNT$228MNT$41.3M

Quarterly statements and history in the cockpit →

Foresee Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%SECARE005250AVIR600538002168368AINO1720INDSWFTLAB301509MYX1875SOLARAALEMBICLTDRLMD6576.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Foresee Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×SECARE005250INOINDSWFTLAB00079018756883026576.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Foresee Pharmaceuticals is the large dot.

Foresee Pharmaceuticals competitors and peer comparison

How Foresee Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Foresee Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure6576.TWOPeer medianRank in peer set
1-month return-9.9%-6.1%8th lowest of 21
6-month return-11.5%-22.1%9th highest of 21
Distance from 52-week high-25.4%-38.0%7th highest of 21
Revenue growth (TTM)+6.4%+2.5%7th highest of 19
Operating margin-104.5%3.7%3rd lowest of 19
EV / Sales21.4×3.3×2nd most expensive of 19
ROIC minus cost of capital-56.8 pp-7.1 pplowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%1.2×19.0%-0.9%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%4.8×n/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%2.4×38.3%-3.2%
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%

Questions

Which companies are Foresee Pharmaceuticals's closest peers?
The cockpit's peer set: Swedencare (SECARE.ST), GC Corp. (005250.KS), Atea Pharmaceuticals (AVIR), Beihai Gofar Chuanshan Biological (600538.SS), Chongqing Hifuture Information Technology (002168.SZ), Kitazato (368A.T), Inovio Pharmaceuticals (INO), Standard Chemical & Pharmaceutical (1720.TW).
Is Foresee Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 21.4× against a peer median of 3.3×, 2nd most expensive of 19 in its peer set.
How has Foresee Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -11.5% against -22.1% for the median peer; over one year -10.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.